FDA review takes 1012 months under standard review, or approximately 6 months under priority review (if granted), projecting approval between Q3 2027 and Q1Q2 2028, with commercial launch following 13 months later
Your care team can help you understand options for changes, pauses, or next steps based on your program
Semaglutide is not known to affect clotting function, but persistent bruising may warrant investigation, particularly in patients with additional risk factors
Investigational Misconceptions and Weight Outcomes With Semaglutide [PMID: 41140721] Laboratory literature summary: investigational Misconceptions and Weight Outcomes With Semaglutide
However, concentrations up to 50% have been reported in moisturizers
These therapies, originally developed for glucose control, now show robust benefits in weight management